New drug aims to tame severe side effects, let cancer patients resume lifesaving treatment
NCT ID NCT07313202
Summary
This study is testing a drug called Ivarmacitinib for people with advanced solid tumors who had to stop a promising type of cancer treatment (immunotherapy) because of severe side effects. The goal is to see if Ivarmacitinib can help control these side effects so that patients might be able to safely restart their immunotherapy. The study will enroll 72 participants who are divided into two groups based on the current status of their side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED SOLID TUMORS WHO DISCONTINUED TREATMENT DUE TO IRAE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.